z-logo
open-access-imgOpen Access
Allopurinol is the most common cause of DRESS syndrome in Hungarian patients
Author(s) -
Kinyó Ágnes,
ÓnodiNagy Katinka,
Varga Erika,
Németh István Balázs,
Korom Irma,
Gyulai Rolland,
Kemény Lajos,
BataCsörgõ Zsuzsanna
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s3-p17
Subject(s) - medicine , dermatology , toxic epidermal necrolysis , culprit , eosinophilia , exfoliative dermatitis , maculopapular rash , lamotrigine , allopurinol , drug eruption , erythema multiforme , angioedema , erythroderma , rash , surgery , drug , epilepsy , psychiatry , myocardial infarction
Results There were 77 total cases (24 male and 53 female; age range: 19-88 years; mean age 67 years). The most common culprit drug was allopurinol, followed by carbamazepine, lamotrigine, clindamycin and strontium ranelate. Indications for allopurinol therapy in all cases were asymptomatic hyperuricaemia. The time period from using the culprit agent to onset of the drug reaction ranged from 6 to 90 days. with a mean time of 28.4 days. The longest latency period (43.5 days) was for strontium ranelate. Four distinct patterns of cutaneous involvement were identified: a morbilliform, maculopapular exanthema (48 cases), an exfoliative erythroderma (21 cases), an urticated papular exanthem (4 cases) and an erythema multiforme-like reaction (4 cases). Pathologic changes observed were erythema multiforme, superficial spongiotic dermatitis with eosinophilia and lichenoid dermatitis. Impairment of liver and renal functions and blood dyscrasia were frequent complications. Most patients were treated with systemic corticosteroids. The mortality rate was 5.2%. Conclusion High eosinophil count, atypical lymphocytes were poor prognostic factors in our patients with DRESS. Early diagnosis and prompt intervention therapy are essential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here